Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPACT: Adenosine Pre-Medication in Primary PCI
NCT07536802Phase 4Recruiting
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of adenosine in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by National Institute of Cardiovascular Diseases. Primary endpoint: Incidence of slow flow/no-reflow (TIMI flow grade 0-II). Started Jun 2025; status: recruiting.
02
Drugs
adenosine
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07536802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07536802.